Citigroup Downgrades Phreesia to Neutral, Lowers Price Target to $10
3/31/2026
Impact: -75
Healthcare
Citigroup analyst Daniel Grosslight has downgraded Phreesia (NYSE: PHR) from a Buy rating to Neutral. The price target for the stock has been reduced significantly from $25 to $10.
AI summary, not financial advice
Share: